Kimberly Ha’s Post

��️ Celebrating #NationalCancerResearchMonth! Join us in recognizing a significant study published in the International Journal of Particle Therapy, which explores the benefits of intensity-modulated proton therapy (IMPT) for patients with locally advanced non-small cell lung cancer (NSCLC). 🔬 Led by Dr. Jimmy S. Patel this research reveals that IMPT significantly reduces the effective radiation dose to immune cells (EDIC) compared to standard intensity-modulated radiotherapy (IMRT). This reduction in EDIC is crucial—it helps maintain the integrity of patients' immune system during treatment, which is associated with better overall survival and fewer complications. 🌟 By minimizing damage to immune cells, IMPT reduces lymphopenia, preserving the immune system’s ability to fight cancer and enhancing the benefits of immunotherapy to  improve quality of life and treatment outcomes. These results suggest that proton therapy could be a game-changer in managing the toxicity often associated with radiation treatments, paving the way for safer, more effective cancer care. 📖 To learn more about how this study advances NSCLC treatment and its implications for future cancer therapy, read the full article here: https://lnkd.in/gAVhhDrg Review more clinical research on Proton Therapy: https://lnkd.in/gCe2m4RZ Emory University School of Medicine University of Pennsylvania School of Medicine UPMC Hillman Cancer Center Jimmy S. Patel Neal McCall, MD Matthew Thomas Jun Zhou Kristin Higgins, MD Jeffrey Bradley Sibo Tian Mark McDonald  Aparna Kesarwala  William A. Stokes #CancerResearch #ProtonTherapy #PatientCare #HealthcareInnovation

𝐀𝐈 𝐔𝐧𝐯𝐞𝐢𝐥𝐬 𝐏𝐫𝐞𝐝𝐢𝐜𝐭𝐢𝐯𝐞 𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐟𝐨𝐫 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐬𝐩𝐨𝐧𝐬𝐞 🧬 Advancements in AI for biomarker prediction and efficacy validation have the potential to redefine the landscape of future immunotherapy treatments. 💡 𝐊𝐞𝐲 𝐃𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐏𝐨𝐢𝐧𝐭𝐬: - How does the QVT biomarker use AI to predict lung cancer patient responses to immunotherapy? - What role does the machine learning algorithm play in predicting patient responses to immunotherapy, and how can it impact future clinical trials? ➡️ Find out here: https://hubs.la/Q02d-dgj0 #OGBiomarkers #Biomarkers24 #LungCancer #Immunotherapy

A novel treatment approach combining low-dose radiotherapy with immune checkpoint inhibitors has shown promising results in driving tumor regression and enhancing antitumor immunity in extensive-stage small cell lung cancer (ES-SCLC). This combined therapy, evaluated in a phase II clinical trial, demonstrated a high objective response rate and improved progression-free survival in treatment-naive ES-SCLC patients. The regimen involving low-dose radiotherapy and chemoimmunotherapy was found to be safe and effective, offering new insights and potential therapeutic strategies for improving outcomes in ES-SCLC patients. #lungcancer #immunotherapy #clinicaltrial #cancerresearch #SCLC #checkpointinhibitors https://lnkd.in/ePMVfbBN

Order your 'Global Alpha-Particle Radiotherapy Market - Forecasts to 2029' FREE Sample Report via https://lnkd.in/d63y-5px Exciting developments lie ahead in the healthcare sector, particularly in the realm of alpha-particle radiotherapy! By 2029, groundbreaking advancements are anticipated to propel this market forward, revolutionizing cancer treatment as we know it. One of the key advancements driving the alpha-particle radiotherapy market is the refinement of targeting techniques. With improved precision in delivering radiation to cancer cells, this therapy promises to minimize damage to surrounding healthy tissue, reducing side effects and enhancing patient outcomes. Moreover, advancements in radiopharmaceuticals are set to expand the applicability of alpha-particle radiotherapy across a wider range of cancer types. By leveraging innovative compounds that specifically target cancer cells, researchers are unlocking new possibilities for personalized treatment approaches, tailoring therapies to individual patients' needs. But perhaps most exciting is the potential for combining alpha-particle radiotherapy with other treatment modalities, such as immunotherapy. By harnessing the synergistic effects of these therapies, healthcare professionals aim to unleash a powerful arsenal against cancer, boosting efficacy and improving survival rates. As someone passionate about healthcare innovation, I'm thrilled by the prospects of alpha-particle radiotherapy in shaping the future of cancer care. Having witnessed the impact of advanced treatment modalities firsthand, I'm confident that these advancements will bring hope to countless patients and families affected by cancer. However, challenges remain on the horizon, from regulatory hurdles to ensuring equitable access to these cutting-edge therapies. It's imperative for stakeholders across the healthcare ecosystem to collaborate closely, driving forward the research, development, and adoption of alpha-particle radiotherapy for the benefit of patients worldwide. So, what are your thoughts on the future of alpha-particle radiotherapy by 2029? I'd love to hear your insights and perspectives in the comments below! Let's continue the conversation and together, shape the future of cancer treatment. Alpha Tau Medical Bayer Alpha-9 Oncology Mariana Oncology RayzeBio ARTBIO Fusion Pharmaceuticals Aktis Oncology Radiomedix, Inc. Atley Solutions #GlobalAlphaParticleRadiotherapyMarket #GlobalMarketEstimates #GME #HealthcareInnovation #AlphaParticleTherapy #CancerTreatment #FutureOfHealthcare #MedicalAdvancements #ResearchAndDevelopment

Guy Mozolowski, COO of Oxford Cancer Biomarkers, discusses how the leading cancer research facility uses AI to create personalised cancer treatment pathways. The mission is to develop precision oncology diagnostic technology, providing patients and clinicians with the tools to create personalised cancer treatment. We know this will improve patient outcomes and drive cost savings within healthcare systems. Oxford Cancer Biomarkers (OCB) has engineered technology that enables clinicians to better understand a patient’s cancer and tailor their treatment. #PersonalisedCancerTreatment #AI #Cancer #CancerTreatment Click the link below to discover more ⬇ https://bit.ly/4cxIQDA

New study in Med by Cell Press of the phase 2 MATCH trial evaluating low-dose radiotherapy + chemoimmunotherapy in extensive-stage small cell lung cancer.

One of the most important component in #cancer treatment is Time 🔔 Yesterday i had the privilege to have a course about #radiotherapy and all the possibilities that this discipline can offer to save patients life's. Collaboration between medical staff is the 🔑 to a successful approach to cancer treatment. Immunotherapy has revolutionized the clinical management of many malignancies but is infrequently associated with durable objective responses when used as a standalone treatment approach, calling for the development of combinatorial regimens with superior efficacy and acceptable toxicity. Radiotherapy, the most commonly used oncological treatment, has attracted considerable attention as a combination partner for immunotherapy owing to its well-known and predictable safety profile, widespread clinical availability, and potential for immunostimulatory effects. https://lnkd.in/ewbqHjnt #oncology #healthcare #medicine #science

A pivotal study leveraging scRNA-seq and spatial transcriptomics, provides a detailed mapping of cellular behaviors within colorectal tumors undergoing anti-PD1 therapy. The study identified distinct cellular dynamics that correlate with varied responses to ICB. These insights elucidate why some tumors exhibit better therapeutic outcomes and lays the groundwork for developing precision therapies tailored to individual tumor profiles. #Immunotherapy #ColorectalCancer #scRNASeq #SpatialTranscriptomics #PrecisionOncology

🎗️ Navigating Breast Cancer Treatment: Integrating Novel Therapies with Radiotherapy through Value-Based Healthcare 🎗️ In the dynamic landscape of breast cancer treatment, innovation drives personalized therapies. Yet, the challenge lies in safely integrating new systemic treatments with radiotherapy within a value-based healthcare (VBHC) framework. While promising, data on combining these therapies remain limited, emphasizing the need for collaborative research efforts. By leveraging VBHC principles, we aim to optimize patient outcomes and ensure that each stride towards progress is grounded in evidence and compassion. How can we ensure optimal patient outcomes while navigating this intersection of innovation and value? #VBHC #BreastCancer #Innovation #Radiotherapy #Immunotherapy #PatientCentricity #ValueBasedCare

⏰ It's time to Explore the mysteries of tumor therapy with us! 💕 Tips! Welcome to your submission (Indexed in PubMed/Scopus and #GoogleScholar with no #APCs) 📚 New #CaseReport sharing! Happy reading! 🎬 Oligometastatic esophageal cancer cured by systemic therapy combined with radiotherapy to primary tumor and metastasis (metastasis-directed therapy)—small case series 📖 This case report explores the effectiveness of a combined systemic therapy and radiotherapy approach for treating primary and metastatic tumors in patients with oligometastatic esophageal cancer. The results indicate that this treatment regimen may significantly improve patient survival rates and quality of life while reducing the volume of metastatic lesions. 📝 Authors: Mohan Hingorani * , Hannah Stubley Academic Editor: Giulia Martini, MD, University of Campania “Luigi Vanvitelli”, Italy 🏃♂️ Welcome to read, forward, and share the article! https://lnkd.in/geRdiJHE #Oligometastasis #EsophagealCancer #Radiotherapy